Semaglutide modulates pro-inflammatory neutrophil phenotype induced by supraphysiological levels of the adipokine FABP4 in patients with cardiovascular disease.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Antidiabetic drugs for treatment of cardiovascular disease Lipid Metabolism, Metabolic Syndrome, Diabetes ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by